Skip to main content

Loading market data...

BIIB

Biogen Inc.

NASDAQ • United states

$242.93

+$9.45

(+4.05%)

Source: Yahoo Finance · Quote time Oct 20, 2026 17:48 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Biogen Inc. (BIIB)

Unavailable

Quotes may be delayed

$35.89B

Market Cap

833,554

Volume

26.2

P/E Ratio

Unavailable

Div Yield

Biogen Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 225 BINNEY STREET, CAMBRIDGE, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

6 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Biogen Inc..

29 Jul 2026

Biogen Inc. filed Form 10-Q

Biogen Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

29 Jul 2026

Biogen Inc. reported Operating or financial results

Biogen Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

2 Jul 2026

Biogen Inc. reported Operating or financial results

Biogen Inc. filed an 8-K covering operating or financial results.

11 Jun 2026

Biogen Inc. reported Shareholder voting results

Biogen Inc. filed an 8-K covering shareholder voting results.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$2.91B

Total assets (USD)$29.48B

Total liabilities (USD)$10.83B

Shareholders' equity (USD)$14.80B

Long-term debt (USD)$6.29B

Debt due within a year (USD)$0

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 31 Mar 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q1 2026	$2.48B	Unavailable	$319.50M	$2.15	10-Q · 29 Apr 2026
Q4 2025	$2.28B	Unavailable	−$48.80M	Unavailable	10-K · 6 Feb 2026
Q3 2025	$2.53B	Unavailable	$466.50M	$3.17	10-Q · 30 Oct 2025
Q2 2025	$2.65B	Unavailable	$634.80M	$4.33	10-Q · 31 Jul 2025
Q1 2025	$2.43B	Unavailable	$240.50M	$1.64	10-Q · 1 May 2025
Q4 2024	$2.45B	Unavailable	$266.50M	Unavailable	10-K · 12 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $244.43

0.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

17

⏸️

Hold

6

📉

Sell

1

24 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 17:49 UTC Targets range 175.00–310.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

2

Oct 2026

Godbout Sean

Chief Accounting Officer

Option exercise

Unavailable per share

27 shares

2

Oct 2026

Godbout Sean

Chief Accounting Officer

Tax withholding

$219.88 per share

8 shares

4

Aug 2026

Minor Lloyd

Director

Open-market sale

$200.96 per share

593 shares

3

Aug 2026

Minor Lloyd

Director

Open-market sale

$203.34 per share

593 shares

9

Jun 2026

HAWKINS WILLIAM A

Director

Grant or award

Unavailable per share

1,505 shares

9

Jun 2026

SHERWIN STEPHEN A

Director

Grant or award

Unavailable per share

1,505 shares

9

Jun 2026

Rowinsky Eric K

Director

Grant or award

Unavailable per share

1,505 shares

9

Jun 2026

Mantas Jesus B

Director

Grant or award

Unavailable per share

1,505 shares

9

Jun 2026

LANGER SUSAN

Director

Grant or award

Unavailable per share

1,505 shares

Top Shareholders

Vanguard Group Inc

28,121,957 shares

3.099% change

12/31/2025

Fmr Llc

18,217,239 shares

42.177% change

6/30/2026

Blackrock, Inc.

15,985,736 shares

-45.832% change

6/30/2026

Primecap Management Co/Ca/

15,154,606 shares

2.69% change

6/30/2026

Vanguard Capital Management Llc

9,651,117 shares

-32.54% change

6/30/2026

State Street Corp

7,344,327 shares

-47.589% change

6/30/2026

Vanguard Portfolio Management Llc

6,604,936 shares

-44.665% change

6/30/2026

Geode Capital Management, Llc

4,449,295 shares

-30.671% change

6/30/2026

Wellington Management Group Llp

3,117,469 shares

-2.921% change

6/30/2026

Norges Bank

2,580,033 shares

-32.764% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 17:49 UTC· 1 day ago

Research coverage and investment tools

Biogen Inc. (BIIB) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$242.93 on 20 Oct 2026. That is 98% of the way from its 52-week low of US$138.00 to its 52-week high of US$244.65. Its market capitalisation was US$35.89 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q1 2026	$2.48B	Unavailable	$319.50M	$2.15	—	—	$594.30M	10-Q · 29 Apr 2026 (opens in a new tab)
Q4 2025	$2.28B	Unavailable	−$48.80M	Unavailable	—	—	$468.00M	10-K · 6 Feb 2026 (opens in a new tab)
Q3 2025	$2.53B	Unavailable	$466.50M	$3.17	—	—	$1.23B	10-Q · 30 Oct 2025 (opens in a new tab)
Q2 2025	$2.65B	Unavailable	$634.80M	$4.33	—	—	$134.30M	10-Q · 31 Jul 2025 (opens in a new tab)
Q1 2025	$2.43B	Unavailable	$240.50M	$1.64	—	—	$222.20M	10-Q · 1 May 2025 (opens in a new tab)
Q4 2024	$2.45B	Unavailable	$266.50M	Unavailable	—	—	$721.60M	10-K · 12 Feb 2025 (opens in a new tab)

Cash and equivalents: $2.91B
Total assets: $29.48B
Total liabilities: $10.83B
Shareholders' equity: $14.80B
Long-term debt: $6.29B
Debt due within a year: $0

SCHEDULE 13G/A · 6 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Biogen Inc..
10-Q · 29 Jul 2026

Biogen Inc. filed Form 10-Q (opens in a new tab)

Biogen Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 29 Jul 2026

Biogen Inc. reported Operating or financial results (opens in a new tab)

Biogen Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 2 Jul 2026

Biogen Inc. reported Operating or financial results (opens in a new tab)

Biogen Inc. filed an 8-K covering operating or financial results.
8-K · 11 Jun 2026

Biogen Inc. reported Shareholder voting results (opens in a new tab)

Biogen Inc. filed an 8-K covering shareholder voting results.

Insider	Date	Transaction	Shares	Average price	Filing
Godbout Sean Chief Accounting Officer	2 Oct 2026	Option exercise (M)	+27	—	Form 4 (opens in a new tab)
Godbout Sean Chief Accounting Officer	2 Oct 2026	Tax withholding (F)	−8	$219.88	Form 4 (opens in a new tab)
Minor Lloyd Director	4 Aug 2026	Open-market sale (S)	−593	$200.96	Form 4 (opens in a new tab)
Minor Lloyd Director	3 Aug 2026	Open-market sale (S)	−593	$203.34	Form 4 (opens in a new tab)
HAWKINS WILLIAM A Director	9 Jun 2026	Grant or award (A)	+1,505	—	Form 4 (opens in a new tab)
SHERWIN STEPHEN A Director	9 Jun 2026	Grant or award (A)	+1,505	—	Form 4 (opens in a new tab)
Rowinsky Eric K Director	9 Jun 2026	Grant or award (A)	+1,505	—	Form 4 (opens in a new tab)
Mantas Jesus B Director	9 Jun 2026	Grant or award (A)	+1,505	—	Form 4 (opens in a new tab)
LANGER SUSAN Director	9 Jun 2026	Grant or award (A)	+1,505	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	28,121,957	3.099%
Fmr Llc	6/30/2026	18,217,239	42.177%
Blackrock, Inc.	6/30/2026	15,985,736	-45.832%
Primecap Management Co/Ca/	6/30/2026	15,154,606	2.69%
Vanguard Capital Management Llc	6/30/2026	9,651,117	-32.54%
State Street Corp	6/30/2026	7,344,327	-47.589%
Vanguard Portfolio Management Llc	6/30/2026	6,604,936	-44.665%
Geode Capital Management, Llc	6/30/2026	4,449,295	-30.671%
Wellington Management Group Llp	6/30/2026	3,117,469	-2.921%
Norges Bank	6/30/2026	2,580,033	-32.764%

Previous close: 233.48 USD
Day range: 236.24 – 244.65 USD
52-week range: 138.00 – 244.65 USD
Volume: 833,554
Market cap: $35.89B
Average volume: 982,666
P/E ratio: 26.2
EPS (FY 2025, diluted): 8.79 USD
Shares outstanding: 147.75M
Beta (5Y monthly): 0.11

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 17:48 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:25 UTC· 7 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for BIIB yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.